{"brief_title": "Phase I Safety Study of Anti-HIV Immune Serum Globulin (Human)", "brief_summary": "To investigate the potential benefit of providing passive immunity with hyperimmune anti-HIV human serum.", "condition": ["HIV Infections"], "intervention_type": ["Drug"], "intervention_name": ["Anti-HIV Immune Serum Globulin (Human)"], "criteria": "Inclusion Criteria Patients must have: - Proof of HIV infection. - Diagnosis of asymptomatic HIV infection or early AIDS related complex (ARC) with no zidovudine (AZT) or other anti-HIV therapy. OR a diagnosis of AIDS and = or > 3 months of AZT therapy. Exclusion Criteria Co-existing Condition: Patients with the following conditions or symptoms are excluded: - HIV-induced neurological disease. - IgA negative. Concurrent Medication: Excluded: - Immunomodulating agents. - Steroids. - Interferons. Patients with the following are excluded: - Active substance abuse. - Use of immunomodulating drugs such as steroids or interferons. - HIV-induced neurological disease. - IgA negative. Required with a diagnosis of AIDS: - = or > 3 months of zidovudine (AZT) therapy. Active substance abuse.", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "keyword": "Immunization, Passive", "mesh_term": ["HIV Infections", "Immune Sera"], "id": "NCT00002036"}